IBT B Stock Overview
A clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Infant Bacterial Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 34.80 |
| 52 Week High | SEK 135.00 |
| 52 Week Low | SEK 21.70 |
| Beta | 1.13 |
| 11 Month Change | 7.08% |
| 3 Month Change | -66.86% |
| 1 Year Change | -60.90% |
| 33 Year Change | -52.33% |
| 5 Year Change | -76.95% |
| Change since IPO | -67.32% |
Recent News & Updates
Recent updates
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Aug 02
Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment
May 02Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans
Apr 03Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation
Sep 16We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
May 11We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate
Sep 23We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely
Apr 07We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Dec 15We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Aug 25We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate
May 06Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)
Feb 07Shareholder Returns
| IBT B | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -16.3% | -0.6% | -1.2% |
| 1Y | -60.9% | 37.3% | 20.9% |
Return vs Industry: IBT B underperformed the Swedish Pharmaceuticals industry which returned 37.3% over the past year.
Return vs Market: IBT B underperformed the Swedish Market which returned 20.9% over the past year.
Price Volatility
| IBT B volatility | |
|---|---|
| IBT B Average Weekly Movement | 20.2% |
| Pharmaceuticals Industry Average Movement | 11.0% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in SE Market | 10.9% |
| 10% least volatile stocks in SE Market | 3.1% |
Stable Share Price: IBT B's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: IBT B's weekly volatility has increased from 12% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 9 | Staffan Stromberg | www.ibtherapeutics.com |
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies `to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants.
Infant Bacterial Therapeutics AB (publ) Fundamentals Summary
| IBT B fundamental statistics | |
|---|---|
| Market cap | SEK 495.75m |
| Earnings (TTM) | -SEK 142.27m |
| Revenue (TTM) | SEK 69.00k |
6,794x
P/S Ratio-3.3x
P/E RatioIs IBT B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBT B income statement (TTM) | |
|---|---|
| Revenue | SEK 69.00k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 69.00k |
| Other Expenses | SEK 142.34m |
| Earnings | -SEK 142.27m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 14, 2024
| Earnings per share (EPS) | -10.56 |
| Gross Margin | 100.00% |
| Net Profit Margin | -206,186.96% |
| Debt/Equity Ratio | 0% |
How did IBT B perform over the long term?
See historical performance and comparison